The abstract is read at the publisher; the summary is JClub's.
SIMMPYRA1 and SIMMPYRA2 suppress triple-negative breast cancer growth by selectively inhibiting STAT3 Y705 phosphorylation, blocking activation at low micromolar concentrations in PDX models.
- Why it matters: TNBC has poor survival and few effective therapies, and STAT3 signaling is a key vulnerability that needs more selective inhibition strategies.
- What they did: From an in silico screen of 32 benzothiophene analogs, SIM1 and SIM2 were synthesized and tested with binding assays and phospho-STAT inhibition studies, showing reduced phospho-STAT3 at Y705.
- The result: Apoptosis and target-validation experiments using TNBC cells expressing phosphomimetic Y705D STAT3, plus metabolic stability and in vivo tumor-growth tests after STAT3 overexpression, support that blocking STAT3 Y705 phosphorylation suppresses TNBC growth.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.